

Quarterly Presentation – Q3 FY17

January 2017



Important Disclosure

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.


Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.



Financial Performance

Key Highlights – Q3 FY17



Net debt of INR 1,818 mn as on 31st Dec, 2016, reflecting net debt to equity ratio of 0.19

Robust 21.9% growth YoY in EBITDA to INR 565 mn in Q3 FY17, reflecting an EBITDA margin of 12.4%



NH at a Glance

As on 1st Jan 2017



49	Healthcare Facilities	
18	Owned / Operated hospitals ⁽¹⁾	4,369 Beds
4	Managed hospitals (2)	720 Beds
7	Heart centres	376 Beds
19	Primary healthcare facilities (3)	10 Beds
1	Hospital in Cayman Islands	101 Beds



6,647 Capacity Beds

5.576 Operational Beds

2.7 mn Average effective capital cost per operational bed



30+ Specialities



309 (5)

Daily Average Surgeries and Procedures



14,074


Full-time employees and associates including 2,915 doctors

1) NH owns the P&L responsibility




⁽³⁾ Includes clinics, information centres, etc

⁴⁾ Based on (Gross Block for Fixed Assets (adjusted for non-cash government grant provision) + Capital Work in Progress (CWIP)) / Number of operational beds as of 31st Dec 2016. excludes Managed Hospitals and C

















(8) Percentages might not add up to 100% due to rounding off

⁽¹⁾ NH owns the P&L responsibility

⁽²⁾ Includes managed hospitals, clinics, learning and development, teleradiology, etc

⁽³⁾ As percentage of IP and OP revenue: Schemes include CGHS, ESIS, other state government schemes. Excludes E City, Sarjapur, Hosur, HSR clinics and Berhampore unit


⁽⁴⁾ Includes Insurance-covered patients, corporate patients (including public sector undertakings)


⁽⁵⁾ Calculated on operating revenue of owned / operated hospitals


⁽⁶⁾ Others include hospitals at Jaipur, Raipur, Ahmedabad and newly commissioned facility at Kakriyal, Jammu


⁽⁷⁾ Calculated on IP revenue; 6 core specialities (cardiac sciences, renal sciences, oncology, neurosciences, gastroenterology and orthopaedics) account for ~90% of IP revenue in Q3 FY17 (excludes Vaishno Devi unit)

Operational Review










⁽¹⁾ Excludes Managed Hospitals, Berhampore & Cayman facility for Q3 FY17 and excludes Managed Hospitals, MMRHL & Cayman facility for Q3 FY16


⁽²⁾ Occupancy rate is calculated on total Census beds (Census beds exclude recovery, pre operative, dialysis, emergency, day care, etc.); Occupancy of 48.7% on total operational beds in Q3 FY 17 as against 51.7% in Q3 FY 16

Cluster Split



- (1) Includes Managed hospitals and excludes Cayman facility
- (2) Excludes Managed hospitals and Cayman facility
- (3) Karnataka and Eastern clusters include 1 managed hospital each while Others include 2 managed hospitals
- (4) Occupancy is calculated on Census beds; Occupancy of 48% for Karnataka cluster, 56% for Eastern cluster and 45% for Others respectively on total operational beds
- (5) Percentages in pie might not add up to 100% due to rounding off
- (6) Does not include Berhampore hospital data as NH exited from it in November 2016
- (7) Does not include Hyderabad hospital data as NH exited from it in April 2016

Maturity Profile



⁽¹⁾ Maturity determined as on 31st March'16 except Jammu, commissioned on 8th April'16, Hyderabad and Berhampore excluded

⁽²⁾ Includes Managed hospitals and excludes Cayman facility

⁽³⁾ Excludes Managed hospitals and Cayman facility

⁽⁴⁾ EBITDA before rental/revenue share and before allocation of any corporate expenses

⁽⁵⁾ Occupancy is calculated on Census beds; Occupancy of 52% for > 5 years bucket, 43% for 3-5 years, 43% for < 3 years, 58% for acquired units respectively on total operational beds


⁻ Over 5 years include NICS,MSMC, RTIICS, units at Jaipur, Jamshedpur and 2 other units at Kolkata viz. RTSC, RNN

^{- 3-5} years include units at Raipur, Ahmedabad, Mysore, and Shimoga


⁻ Less than 3 years include 4 managed hospitals and 4 units at Whitefield, HSR, Guwahati and Kakriyal

⁻ Acquired facilities include 2 units of MMRHL, Kolkata and unit at Barasat (Kolkata)

Profitability Snapshot



- 9 months FY17 EBITDA grew by 32.8% YoY, reflecting an improvement of 148 bps in margin
- Heart centres clocked an EBITDAR margin of 19.6%⁽¹⁾ in Q3 FY17
- Hospital at Cayman Islands achieved operating revenue of USD 8.4 mn and EBITDA of USD 0.8 mn in Q3 FY17



⁽¹⁾ EBITDA before rental/revenue share and before allocation of any corporate expenses

⁽²⁾ Categories have been calculated as Consumable Expenses = Purchase of medical consumables, drugs and surgical equipment, net of changes in inventories of medical consumables, drugs and surgical equipment; Employee (exc. Doctors) Benefits and Doctors expenses = Employee benefits + Professional fees to doctors; Others = all other expenses



Financial Performance

Figures in INR mn, unless stated otherwise

Profit and Loss Statement ⁽¹⁾			
Particulars	Q3 FY17	9M FY17	
Total Operating Revenue	4,553	13,946	
Purchase of medical consumables, drugs and surgical equipment- Net of change in Inventory	1,068	3,275	
Employee (Excluding Doctors) Expenses	879	2,588	
Doctors Expenses	1,023	3,079	
Other Admin Expenses	1,056	3,317	
Total Expenses	4,027	12,259	
Other Income	39	118	
EBITDA	565	1,805	
Depreciation and Amortization	200	587	
Finance Costs	55	162	
Profit Before Tax & Exceptional Items	309	1,055	
Exceptional Items	13	13	
Tax Expense	109	374	
PAT before MI and share of loss of associates	187	669	
Share in (loss) of associates and MI	(16)	(61)	
PAT after MI and share of loss of associates	170	608	
Total Comprehensive Income, net of tax	167	610	

Key Balance Sheet Items ⁽¹⁾				
Particulars	31st Dec 2016			
Shareholder Equity	9,445			
Total Debt	2,107			
Long term debt including current maturities	1,964			
Short term debt	143			
Net Block	10,023(2)			
Goodwill	581			
Non Current Investment	981			
Net receivables	1,822			
Cash and cash equivalents	289			

As on December 31st, 2016, the consolidated net debt was Rs 1,818 mn representing a net debt to equity ratio 0.19

⁽¹⁾ Figures might not equal the reported numbers due to rounding off

⁽²⁾ Net Block includes non-cash government grant provision of Rs 1,448 mn




Project Pipeline

Location	Estimated time for Commencement	Type of hospital	No of beds	Туре
Mumbai	Within next 2 months	Multispeciality, paediatric	297	Operation and management basis
Bhubaneshwar	NA	Multispeciality	220	Construct and operate hospital on leasehold land (Awaits Govt of Odisha's acceptance for alternate land parcel)
Kenya	Within next 48 months	Multispeciality	130	Minority equity stake and management agreement with NH

- Growth trajectory on track through the above projects as well as several projects under discussion
- Emphasis on "asset right" capital deployment model and the engagement framework which provide us the flexibility to limit our capital investments primarily to medical equipment
- Focus to maintain a balanced approach while evaluating organic and inorganic opportunities to fuel future expansion

Shareholding Pattern



⁽¹⁾ Includes 2.8% held by NHAPL (Narayana Health Academy Private Limited)

⁽²⁾ PE investors include CDC, Asia Growth Capital and JP Morgan who have been shareholders prior to the IPO